SOMAÍ Prescription drugs is proud to announce a strategic partnership with Releaf, the UK’s fastest-growing medical hashish clinic, to deliver progressive cannabis-based therapies to Releaf’s quickly increasing affected person base.
As a part of the collaboration, SOMAÍ Prescription drugs will present Releaf sufferers with unique entry to its Indica Necessities product line. They will even produce other formulations obtainable sooner or later, together with our mint line, particularly designed to boost affected person outcomes and compliance. SOMAÍ’s broadest cannabis-based extract portfolio focuses on assembly affected person wants by providing improved efficiency and better-tasting therapies. Every components combines numerous THC/CBD ratios, genetics, and terpene profiles, addressing numerous medical situations.
“At SOMAÍ, we’re continuously innovating to fulfill the evolving wants of sufferers worldwide,” mentioned Michael Sassano, the founder and interim CEO at SOMAÍ Prescription drugs. “Partnering with Releaf permits us to increase our attain to 1000’s of sufferers within the UK who can now entry our high-quality, full-spectrum merchandise, serving to them enhance their high quality of life by means of tailor-made medical hashish therapies. With over 100+ extract SKUs and an array of indoor non-irradiated flower, SOMAÍ presents probably the most complete portfolios to handle numerous affected person wants.”
Releaf stands out within the UK market, being the fastest-growing medical hashish clinic within the UK, with over 3,000 new sufferers becoming a member of the platform every month. Releaf has vertically built-in into the provision chain, together with the one UK-grown cannabis-based medicinal product (CBMP) and a dedication to making sure that remedy plans are by no means interrupted. Releaf’s Affected person Constitution ensures treatment consistency and quick supply, making it a trusted medical hashish supplier within the UK.
This new partnership will bolster Releaf’s mission to supply best-in-class healthcare, providing well timed, evidence-based remedy choices for sufferers in search of reduction from continual situations.
“Since launching Releaf in February ’24 after two years of planning and funding, it’s been so vital for Releaf to kind deep strategic alliances with healthcare-focused suppliers. SOMAÍ ticked all of our bins: long-term ambition, high quality merchandise, innovation paths which can be focussed on healthcare and high quality of life enchancment for sufferers, to call however a couple of,” mentioned Tim Kirby, Chief Govt Officer at Releaf.
“The UK market has stagnated since laws modified to make CBPM obtainable within the UK in 2018 as a result of incumbent suppliers’ lack of ability to go to market successfully and educate and inform the CBPM naive. Releaf has redefined the sector within the UK, and with companions reminiscent of SOMAÍ in lockstep as to market method, we’re set to be as massive as all the sector is at this time (c. 35,000 sufferers) inside 12 months at our present affected person onboarding volumes.”
Each SOMAÍ and Releaf share a dedication to educating sufferers on the advantages of medical hashish by means of evidence-based info and making life-changing therapies accessible. With Releaf’s quickly rising affected person base and SOMAÍ’s progressive product choices, the partnership guarantees to boost the UK’s medical hashish panorama and ship constructive well being outcomes for 1000’s of sufferers.
